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Background: estimates of the size of the undiagnosed HiV-infected 
population are important to understand the HiV epidemic and to plan 
interventions, including “test-and-treat” strategies.
Methods: We developed a multi-state back-calculation model to esti-
mate HiV incidence, time between infection and diagnosis, and the 
undiagnosed population by cD4 count strata, using surveillance data on 
new HiV and aiDS diagnoses. the HiV incidence curve was modelled 
using cubic splines. the model was tested on simulated data and applied 
to surveillance data on men who have sex with men in the netherlands.
Results: the number of HiV infections could be estimated accurately 
using simulated data, with most values within the 95% confidence 
intervals of model predictions. When applying the model to Dutch 
surveillance data, 15,400 (95% confidence interval [ci] = 15,000, 
16,000) men who have sex with men were estimated to have been 
infected between 1980 and 2011. HiV incidence showed a bimodal 
distribution, with peaks around 1985 and 2005 and a decline in 
recent years. Mean time to diagnosis was 6.1 (95% ci = 5.8, 6.4) 
years between 1984 and 1995 and decreased to 2.6 (2.3, 3.0) years in 
2011. By the end of 2011, 11,500 (11,000, 12,000) men who have sex 
with men in the netherlands were estimated to be living with HiV, 
of whom 1,750 (1,450, 2,200) were still undiagnosed. Of the undiag-
nosed men who have sex with men, 29% (22, 37) were infected for 
less than 1 year, and 16% (13, 20) for more than 5 years.
Conclusions: this multi-state back-calculation model will be useful 
to estimate HiV incidence, time to diagnosis, and the undiagnosed 
HiV epidemic based on routine surveillance data.
(Epidemiology 2015;26: 653–660)
Over the past few decades, HiV has changed from an infec-tion invariably culminating in aiDS and death to a chronic 
condition needing early and lifelong treatment to prevent repli-
cation of the virus and to maintain normal cD4+ t cell counts 
(cD4 counts). nevertheless, as the number of individuals diag-
nosed with HiV as well as the number treated for their infection 
continues to increase in europe, HiV infection remains a major 
public health problem. the exact number of people infected 
with the virus remains, however, unknown because many HiV-
infected individuals have not yet been diagnosed. according to 
recent UnaiDS estimates, approximately 900,000 people are 
living with HiV in Western and central europe.1 in european 
countries, recent estimates of the proportion of infected individu-
als who are undiagnosed ranged from 20% to 40%.2–5
accurate estimates of the number of people living with 
HiV, including those not yet diagnosed, are of paramount 
importance for understanding the burden of HiV and the 
need for combination antiretroviral treatment.6 equally rel-
evant are estimates of current trends in HiV incidence and 
uptake of testing, for instance when evaluating the effect on 
the HiV epidemic of “test-and-treat” strategies, where HiV-
positive individuals are offered combination antiretroviral 
treatment immediately, independently of cD4 counts.7 if 
the incidence of new HiV infections over time is known for 
the entire population, the number of individuals living with 
HiV may be estimated using additional data on migration 
and mortality.8,9
as many countries in europe have implemented surveil-
lance systems for HiV infection and aiDS, data are available 
on newly diagnosed HiV infections as well as on aiDS cases.10 
However, since the duration between HiV infection and HiV 
diagnosis is often unknown, they cannot be used as a direct 
measure of HiV incidence.3,11 a growing number of countries 
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also report on cD4 counts at the time of HiV diagnosis.10 cD4 
counts not only provide information on the number of HiV-
infected individuals in need of treatment but also on the dura-
tion of infection. Mathematical tools such as back-calculation 
methods that use data on new diagnoses and cD4 counts around 
diagnosis can provide some insight into the dynamics underly-
ing these observed data by disentangling changes in HiV inci-
dence and changes in testing patterns.3,12–15
We developed a method to simultaneously estimate HiV 
incidence, time between infection and diagnosis, and the size 
of the undiagnosed population, using surveillance data on 
reported HiV and aiDS cases and information on cD4 counts 
at the time of diagnosis.13 We tested the approach on simu-
lated data and applied it to data on men who have sex with 
men (MSM) in the netherlands.
MATERIALS AND METHODS
Mathematical Model
the method used to estimate HiV incidence and time to 
diagnosis is an extension of the model used by Sweeting and col-
leagues3 (simplified model Figure 1; full model eFigure 1; http://
links.lww.com/eDe/a932).13 in brief, the model describes HiV 
progression as a unidirectional flow through different stages of 
the infection that are characterized by cD4 counts or the pres-
ence of aiDS events.16 immediately after infection, all individu-
als first enter a phase of primary HiV infection and then, in the 
absence of antiretroviral treatment, progress to aiDS through up 
to four different cD4 strata. the proportion of patients in each 
cD4 cell stratum immediately after primary infection and the 
progression rates between cD4 strata are based on data from 
seroconverters in the caScaDe collaboration.17,18 a complete 
description of the model and its parameters is given in the eap-
pendix (http://links.lww.com/eDe/a932).
During each stage of infection, patients can be diagnosed 
at a rate that may depend on calendar time. For simplicity, we 
assume that HiV-infected individuals cannot be diagnosed dur-
ing primary infection when antibody responses to HiV have 
not fully developed yet. We considered five distinct historical 
periods for which cD4 stratum-specific diagnosis rates are 
estimated: (1) 1980–1983, during which the first aiDS cases 
were diagnosed; (2) 1984–1995, when serological testing for 
HiV became widely available; (3) 1996–1999, the start of the 
era of combination antiretroviral treatment; (4) 2000–2004; 
and (5) 2005–2012.5,19 Diagnosis rates were approximated as 
a piecewise linear function of calendar time with a different 
slope for each of the five time intervals. thirty different param-
eters were thus necessary to describe diagnosis rates, six for 
each stage of infection. to reduce the number of parameters, 
we assumed that in the first time interval 1980–1983 all diag-
nosis rates are zero except for d5 because no diagnostic tests 
were available at that time and HiV could only be diagnosed 
when aiDS had developed (Figure 1). Furthermore, d5 was 
fixed at a high and constant value over calendar time, reflecting 
the high probability of being diagnosed with HiV when aiDS 
symptoms appear. in addition, we assumed that diagnosis rates 
in the second time interval 1984–1995 were also constant over 
time (see also eappendix; http://links.lww.com/eDe/a932) 
such that the total number of diagnosis rate parameters that 
needed to be estimated from the data is 16. this assumption 
FIGURE 1. Simplified model structure. HIV incidence over calendar time t is denoted by  I t( ) . Immediately after infection, all individuals 
first enter a phase of primary infection. After primary infection, individuals enter at a rate  fi qP  one of four AIDS-free CD4 compartments 
of undiagnosed HIV infection with 
i
if
=
∑ =
1
4
1 . We assume that no HIV-infected individuals immediately progress to AIDS after primary 
infection. In the absence of treatment, individuals progress to the next compartment at a rate  q ii , ,= …( )1 5  until they develop AIDS and 
then die because of AIDS at a rate q5 . During each stage except primary infection individuals can be diagnosed at a rate d ti ( ) , depend-
ing on the stage and on calendar time.
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was motivated by the low number of observed HiV diagno-
ses for the early years of the epidemic due to data truncation 
(see “Fitting to Surveillance Data”) and by the fact that in the 
netherlands HiV testing rates have traditionally been among 
the lowest in europe before the introduction of combination 
antiretroviral treatment.20,21
the HiV incidence curve was approximated using cubic 
M-splines, which allows for high flexibility with relatively few 
parameters.22 it was assumed that the incidence rate started at 
zero in 1980. Further details are given in the Supplementary 
Material (http://links.lww.com/eDe/a932).
Fitting to Surveillance Data
We fitted the above model to different sources of surveil-
lance data from the aiDS therapy evaluation in the netherlands 
(atHena) national observational HiV cohort and the national 
institute of Public Health and the environment in the nether-
lands.23,24 the atHena cohort includes anonymized data from 
all HiV-infected patients living in the netherlands who receive 
care in one of the 27 HiV treatment centers. atHena patients 
are informed of data collection by their treating physician and 
patients can refuse further collection of clinical data according 
to an opt-out procedure. Written informed consent and ethical 
approval is not obtained, as data collection is part of HiV care. 
Surveillance data used in our study included the annual number 
of new HiV diagnoses by cD4 count stratum, the annual num-
ber of new aiDS cases, and the annual number of concurrent 
HiV and aiDS diagnoses (an aiDS diagnosis within 6 weeks of 
HiV diagnosis). the fitting procedure resulted in estimation of 
the diagnosis rates and HiV incidence curve (see eappendix for 
further details; http://links.lww.com/eDe/a932).
annual numbers of HiV diagnoses were available from 
1984 onwards. the cD4 count at the time of diagnosis was 
defined as the first cD4 count within 3 months after diagno-
sis and before start of treatment. Overall, 75% of the patients 
diagnosed from 1984 onwards had a cD4 count available 
at the time of diagnosis. We took missing cD4 counts into 
account by multiplying for each year the estimated number 
of HiV diagnoses in each stratum by the proportion of all 
HiV diagnoses in the same year having a cD4 count. thus, 
we implicitly assumed that patients without cD4 count 
measurement had the same cD4 distribution as those with 
a cD4 measurement (see eappendix; http://links.lww.com/
eDe/a932). the estimated annual numbers of diagnoses by 
cD4 count stratum were then fitted to the observed numbers. 
as the atHena cohort only started in 1998 with retrospec-
tive inclusion of patients from 1996 onwards, patients who 
died befovre 1996 were not included in the database. We 
explicitly accounted for this data truncation by calculating 
the probability that a patient diagnosed in each cD4 stratum 
survived up to 1996 without antiretroviral treatment.19 We 
assumed that mono- or dual therapy, which were available 
before 1996 but not widely used, did not substantially alter 
these survival probabilities.
the model was also fitted to data from the Dutch 
Health inspectorate on the annual total number of aiDS cases 
between 1982 and 1996.16,24 total numbers of aiDS diagnoses 
after 1996 were not used because the probability of progress-
ing to aiDS would be affected by the use of combination anti-
retroviral treatment and incorporating its effect and changes in 
treatment guidelines on when to start antiretroviral treatment 
would make our model much more complicated. instead, from 
1996 onwards, we used atHena data on concurrent HiV/
aiDS diagnoses made before treatment was started and there-
fore not affected by treatment. We did not use data on concur-
rent HiV and aiDS diagnoses before 1996, because patients 
in atHena with an HiV/aiDS diagnosis in that period are a 
biased group of patients who survived up to 1996. the num-
ber of HiV diagnoses and HiV/aiDS cases in 2011 and 2012 
were corrected for a backlog in registration by adding 3% and 
11%, respectively, to the number of cases observed so far.23
We constructed point wise 95% confidence intervals 
(ci) for the parameters and other outcomes via a bootstrap 
procedure (see eappendix; http://links.lww.com/eDe/a932). 
although analyses were done up to and including 2012, we 
report model outcomes at the end of 2011 because of wide 
confidence intervals in 2012. numbers were rounded to the 
nearest 10, 50, or 100 if they were below 1,000, between 1,000 
and 10,000, or above 10,000, respectively.
the number of HiV-infected MSM who were still alive 
by the end of 2011 was estimated by subtracting the cumulative 
number of MSM who died from the cumulative number of HiV 
infections. the number of MSM who died because of aiDS, 
while remaining undiagnosed was calculated from the math-
ematical model. the number of deaths among diagnosed MSM 
was taken from Statistics netherlands (before 2002) or atHena 
(from 2002 onwards).23,24 Since Statistics netherlands has no 
information on transmission risk group, it was assumed that 70% 
of deaths among men were MSM, which is the percentage of 
MSM among male patients in atHena diagnosed before 2002.5
in a secondary analysis, we assumed diagnosis rates to 
be the same for the first three cD4 strata ( d t d t d t1 2 3( ) = ( ) = ( ) ) 
and assumed that d t d t d t4 3( ) = ( ) + ( )symp  with d tsymp ( )  the rate 
of being diagnosed because of HiV-related symptoms. in this 
case, we did not use information on cD4 counts and fitted the 
model to the total annual number of HiV diagnoses instead 
of diagnoses by cD4 count stratum. We also did a multivari-
able sensitivity analysis to investigate the impact of assump-
tions on input parameters on the model outcomes (eappendix; 
http://links.lww.com/eDe/a932).25,26
Simulated Data
We tested our approach by determining the annual number 
of HiV infections and the number of undiagnosed infections in 
three populations of simulated HiV-infected patients generated 
using HiV Synthesis.8,27 in brief, HiV Synthesis is an individual- 
based stochastic simulation model of HiV progression and 
the effect of antiretroviral treatment. Model assumptions and 
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parameters are based on data from observational cohorts and 
clinical trials. although HiV Synthesis can simulate the effect 
of antiretroviral treatment, for our purpose, the most important 
feature is its ability to generate newly diagnosed HiV and aiDS 
cases from prespecified incidence curves and diagnosis rates 
with a validated course of cD4 count changes and progression 
to aiDS and death during untreated HiV infection.27 estimated 
incidence curves were compared with the true curves that were 
used as input in the simulations.
RESULTS
applying our method to simulated data showed that the 
true number of infections could be reconstructed accurately, with 
the majority of true values lying within the estimated 95% confi-
dence intervals (Figure 2). However, the method could not accu-
rately estimate the peak in the true number of infections in the 
mid-1980s, which is most apparent in Figure 2c. nevertheless, 
the method was still able to estimate the number of undiagnosed 
individuals although the difference with the true number was 
larger in most recent years ( Figure 3). in the secondary model, 
which did not use information on cD4 counts at the time of diag-
nosis, the estimated HiV infection curves and undiagnosed pop-
ulation looked similar (eFigures 2 and 3; http://links.lww.com/
eDe/a932), although confidence intervals were wider.
Between 1980 and 2011, a cumulative number of 
15,400 (95% ci = 15,000, 16,000) infections in MSM in the 
netherlands were estimated to have occurred. the number of 
HiV infections peaked around 1985 with 870 (820, 940) new 
infections in that year (Figure 4a). in the 1990s, the num-
ber of infections varied between 200 and 300 per year. Since 
2000, HiV incidence steadily increased and reached levels 
comparable with those in the mid-1980s by 2005, followed by 
a decreasing trend to 590 (400, 780) new infections in 2011.
the mean time between infection and diagnosis if diag-
nosis rates would remain the same as in the year of infection 
is shown in Figure 4B. Between 1980 and 1983, when HiV 
could only be diagnosed once aiDS symptoms appeared, the 
average time between infection and HiV diagnosis for people 
infected in this period, were conditions to have remained as 
they were in this period, would have been 11.6 years. this 
decreased to 6.1 years (95% ci = 5.8, 6.4) in the period 
1984–1995. From 1996 onwards, the time to HiV diagnosis 
steadily decreased to 2.6 (2.3, 3.0) years on average for men 
infected in 2011. in contrast, the actual time between infection 
and diagnosis by year of diagnosis (Figure 4c) was estimated 
to increase from the start of the epidemic to between 7 and 8 
years at the end of the 1990s, and then decreased to 3.6 (3.3, 
4.0) years on average in 2011.
in total, 3150 diagnosed and 100 undiagnosed MSM had 
died by the end of 2011 such that 12,200 (95% ci = 11,700, 
12,800) HiV-infected MSM were estimated to be alive at that 
time (Figure 4D). at the same time, according to atHena 
data, 6% of MSM diagnosed between 1996 and 2011 were 
not in care anymore because they had moved abroad or were 
lost to follow-up. We therefore estimated the total number of 
MSM living with HiV in the netherlands, including those not 
yet diagnosed, to be 11,500 (11,000, 12,000).
Figure 4D shows that the total number of undiagnosed 
MSM has remained around 2000 for the past 15 years. alto-
gether, 1,750 (95% ci = 1,450, 2,200) HiV-infected MSM, or 
11% (10, 14) of all those infected since the start of the HiV 
epidemic, were estimated to be still undiagnosed by the end 
of 2011 (Figure 4D). Of these undiagnosed MSM, 29% (95% 
ci = 22, 37) had been infected for less than 1 year, 54% (47, 
60) were infected 1 to 5 years before, and 16% (13, 20) had 
been infected for more than 5 years. in total, 800 (650, 1,000) 
undiagnosed MSM, or 46% (42, 50), had cD4 cell counts 
below 500 cells/mm3, whereas 28% (24, 31) had cD4 counts 
below 350 cells/mm3.
the multivariable sensitivity analysis showed that 
parameters associated with the earliest stages of infection had 
the largest impact on estimated model outcomes (etable 2; 
FIGURE 2. Estimated and true number of infections for three different simulated HIV epidemics. Black solid lines show the model 
estimates, and dashed lines are 95% confidence intervals. Thin grey lines show results of multivariable sensitivity analyses. Grey dots 
are the true annual number of infections.
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http://links.lww.com/eDe/a932). the largest effect was seen 
in model outcomes before 1996, where there are less data to 
constrain the model fits (Figure 4).
DISCUSSION
Our study shows that by the end of 2011, 11,500 MSM 
were living with HiV in the netherlands, of whom 1,750 were 
still undiagnosed. the annual number of infections around 
2005 was estimated to be at similar levels as in the early phase 
of the HiV epidemic with a declining trend in more recent 
years. Meanwhile, testing rates have increased such that the 
average time from infection to diagnosis has decreased to 2.6 
years for those infected in recent years.
One of the strengths of our back-calculation method is that 
it only uses routinely collected data on HiV and aiDS diagnoses. 
Our approach may therefore easily be applied in other settings 
with similar data availability. Furthermore, using information on 
the stage of the infection at the time of diagnosis, either measured 
by cD4 counts or by a concurrent aiDS diagnosis, our method 
is able to distinguish changes in HiV incidence from changes 
in the probability of being diagnosed.3,5,6,13–15 as our method 
integrates HiV incidence, natural disease progression, and HiV 
diagnosis, estimates of the number of undiagnosed infections 
by disease stage and cD4 stratum are automatically generated. 
the multivariable sensitivity analysis and results from simulated 
data showed that generally our findings were robust to changes 
in input parameters, although less so in calendar years for which 
there were less data to constrain the model fits. also, estimates 
of HiV incidence and the undiagnosed proportion were similar 
when only using total annual numbers of HiV and aiDS diagno-
ses and information on simultaneous HiV/aiDS diagnosis. Our 
approach may therefore still be applicable in settings with no or 
limited (historical) data on cD4 counts.
there are, however, also a number of limitations to our 
study. First, our analysis relies on historical data on aiDS 
cases and HiV diagnoses, which may not be available in all 
countries or for all risk groups. Second, the method uses data 
on case reports, which may be subject to underreporting, mis-
classification of transmission risk group or stage of infection, 
or incomplete information. Underreporting of HiV cases to 
the national surveillance system, which may be quite likely in 
some settings, will lead to underestimates of HiV incidence 
and may also affect estimates of diagnosis rates, for instance, 
when HiV/aiDS diagnoses are less likely to be reported. in 
the netherlands, case reports for MSM diagnosed with HiV 
before 1996 were incomplete, because there is no national 
reporting of HiV diagnoses since the start of the epidemic and 
atHena only started collecting data from 1996 onwards. 
also, cD4 counts at the time of diagnosis were not available 
for all patients, although in more recent calendar years they 
were missing in less than 15% of newly diagnosed patients. 
in particular, when cD4 counts are not missing at random, for 
instance when symptomatic HiV diagnoses are less likely to 
have a cD4 count than nonsymptomatic diagnoses, the time 
to diagnosis can be underestimated. Furthermore, the math-
ematical model only takes into account aiDS-related deaths 
such that HiV incidence may be underestimated when there is 
substantial non-aiDS-related mortality in undiagnosed indi-
viduals. emigration of undiagnosed HiV-infected individuals 
would also yield lower estimates of the annual number of new 
HiV infections. However, we expect only a limited effect of 
prediagnosis mortality and emigration on the estimated num-
ber living with HiV, because both cumulative incidence and 
cumulative number of reported deaths will be affected in the 
same way. Our approach does not explicitly take into account 
migration and may therefore be less suitable for migrant pop-
ulations, many of whom will have been infected in the country 
of origin but cannot be diagnosed in the netherlands before 
arriving.
the rates of cD4 cell decline and onset of aiDS in 
our analysis were based on data from an international cohort 
of HiV-infected individuals with a well-estimated time of 
FIGURE 3. Estimated and true number of undiagnosed infections for three different simulated HIV epidemics. Black solid lines 
show the model estimates, and dashed lines are 95% confidence intervals. Thin grey lines show results of multivariable sensitivity 
analyses. Grey dots are the true annual number of undiagnosed infections.
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infection.17 Whereas cD4 cell decline in these seroconverters 
was similar to that in seroprevalent HiV patients, our method 
ignored differences in progression rates by age, ethnicity, 
viral load, and, possibly, increasing virulence in recent cal-
endar years.28–32 Patients may also have received prophylaxis 
for opportunistic infections thus prolonging the time to onset 
of aiDS. We may therefore overestimate the time to aiDS 
in untreated patients. this is however unlikely to invalidate 
our results as in recent years the majority of HiV patients are 
diagnosed before onset of aiDS. the average time to onset of 
aiDS in the absence of treatment was also longer than in a pre-
vious analysis in the netherlands, which may explain, at least 
in part, why we also estimated a longer time to diagnosis.5,19
Previously, using the Multi-Parameter evidence Synthe-
sis approach, the number of MSM in the netherlands living 
with HiV was estimated to be 11,758 (95% credibility inter-
val = 8,670–17,573) at the beginning of 2008.2,33 Our method 
estimates a lower number of 9,950 (95% ci = 9,550, 10,400) 
infected MSM. We think that part of this difference is explained 
by MSM who opt out of further data collection in atHena, 
approximately 1% of the male patients registered in the cohort. 
as data on transmission risk group were unavailable for these 
men, they were not part of our analysis and this may have led 
to a downward bias in the estimated number of infections. 
also, about 5% of HiV-positive MSM participating in a sexual 
health survey were not yet in care in an HiV treatment centre, 
FIGURE 4. Model outcomes for men who have sex with men (MSM) in The Netherlands. A, Annual number of new HIV infec-
tions; (B) average time from HIV infection to diagnosis by year of infection if diagnosis rates would remain the same as in the year 
of infection; (C) average time from HIV infection to diagnosis by year of diagnosis; (D) total number of individuals living with HIV 
and number of diagnosed and undiagnosed HIV infections, with dots representing the number of diagnosed MSM living with HIV 
according to the ATHENA database. Thin grey lines show results of multivariable sensitivity analyses.
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and would therefore not be in the atHena database, although 
this mainly concerned MSM who were recently diagnosed.34
this study confirms previous findings that in the neth-
erlands, a country with free HiV testing for high-risk groups 
like MSM and universal access to care, a substantial propor-
tion of infected MSM are still unaware of their infection.2,5,19 
We found that 16% of undiagnosed infections have been liv-
ing with HiV for more than 5 years, a proportion similar as 
found in a recent study in France.35 approximately, half of 
the undiagnosed patients had cD4 counts below 500 cells/
mm3 and would thus be eligible for treatment, whereas more 
than a quarter of the undiagnosed infections were already in 
immediate need of treatment (cD4 < 350 cells/mm3).36 Most 
likely, these MSM did not yet suffer from clinical symptoms 
that were severe or specific enough to get tested for HiV. 
Diagnosis and start of combination antiretroviral treatment at 
lower cD4 cell counts have been shown to be associated with 
poorer immunological recovery and increased rates of aiDS 
or death.37,38
the most likely reason for the increase in the number 
of HiV infections is continuing and increasing risky sexual 
behavior, in particular by those unaware that they are infected 
with HiV.5,19,39,40 although MSM who have been diagnosed 
with HiV decrease their sexual risk behavior, this decrease has 
been shown to be of a transient nature, also in MSM not yet 
treated with combination antiretroviral treatment.41,42 even 
though 79% of the diagnosed MSM currently in care have a 
suppressed viral load, and more than a third of MSM diag-
nosed in recent years were infected at most 1.5 years before, 
this has apparently not been enough to lead to a substantial 
decline in HiV incidence in this group.23 to fully curb the HiV 
epidemic in MSM, efforts must therefore continue to increase 
awareness of HiV and promote testing such that the beneficial 
effect of cart, both for the individual patient as well as for 
preventing transmission, can be fully exploited.
in conclusion, we have shown that our method can be 
used to simultaneously estimate HiV incidence, the time 
between infection and diagnosis, and the size and charac-
teristics of the undiagnosed population, using only routine 
surveillance data. Our method can easily be applied by other 
european countries and would be a useful tool to gauge how 
successful interventions like “test-and-treat” strategies are in 
reaching all or almost all undiagnosed HiV infections.
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